Trimethoprim: Difference between revisions

Jump to navigation Jump to search
m (Robot: Automated text replacement (-{{SIB}} +, -{{EH}} +, -{{EJ}} +, -{{Editor Help}} +, -{{Editor Join}} +))
m (Changed protection level for "Trimethoprim" ([Edit=Allow only autoconfirmed users] (expires 20:42, 22 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 20:42, 22 January 2014 (UTC))))
(No difference)

Revision as of 20:42, 8 January 2014

Trimethoprim
Clinical data
Pregnancy
category
  • AU: B3
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • UK: POM (Prescription only)
Pharmacokinetic data
Bioavailability90–100%
Metabolismhepatic
Elimination half-life8–10 hours
Excretionrenal 50–60%
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC14H18N4O3
Molar mass290.32 g/mol

WikiDoc Resources for Trimethoprim

Articles

Most recent articles on Trimethoprim

Most cited articles on Trimethoprim

Review articles on Trimethoprim

Articles on Trimethoprim in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Trimethoprim

Images of Trimethoprim

Photos of Trimethoprim

Podcasts & MP3s on Trimethoprim

Videos on Trimethoprim

Evidence Based Medicine

Cochrane Collaboration on Trimethoprim

Bandolier on Trimethoprim

TRIP on Trimethoprim

Clinical Trials

Ongoing Trials on Trimethoprim at Clinical Trials.gov

Trial results on Trimethoprim

Clinical Trials on Trimethoprim at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Trimethoprim

NICE Guidance on Trimethoprim

NHS PRODIGY Guidance

FDA on Trimethoprim

CDC on Trimethoprim

Books

Books on Trimethoprim

News

Trimethoprim in the news

Be alerted to news on Trimethoprim

News trends on Trimethoprim

Commentary

Blogs on Trimethoprim

Definitions

Definitions of Trimethoprim

Patient Resources / Community

Patient resources on Trimethoprim

Discussion groups on Trimethoprim

Patient Handouts on Trimethoprim

Directions to Hospitals Treating Trimethoprim

Risk calculators and risk factors for Trimethoprim

Healthcare Provider Resources

Symptoms of Trimethoprim

Causes & Risk Factors for Trimethoprim

Diagnostic studies for Trimethoprim

Treatment of Trimethoprim

Continuing Medical Education (CME)

CME Programs on Trimethoprim

International

Trimethoprim en Espanol

Trimethoprim en Francais

Business

Trimethoprim in the Marketplace

Patents on Trimethoprim

Experimental / Informatics

List of terms related to Trimethoprim

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Overview

Trimethoprim (INN) (IPA: Template:IPA) is a bacteriostatic antibiotic mainly used in the prophylaxis and treatment of urinary tract infections. It belongs to the class of chemotherapeutic agents known as dihydrofolate reductase inhibitors. Trimethoprim was formerly marketed by GlaxoWellcome under trade names including Proloprim, Monotrim and Triprim; but these trade names have been licensed to various generic pharmaceutical manufacturers. In clinical use it is often abbreviated TRI or TMP; its common laboratory abbreviation is W.

Mechanism of action

Tetrahydrofolate synthesis pathway

Trimethoprim acts by interfering with the action of bacterial dihydrofolate reductase, inhibiting synthesis of tetrahydrofolic acid. Tetrahydrofolic acid is an essential precursor in the de novo synthesis of the DNA nucleotide thymine. Bacteria are unable to take up folic acid from the environment (i.e. the infection host) and are thus dependent on their own de novo synthesis. Inhibition of the enzyme starves the bacteria of bases necessary for DNA replication.

Co-trimoxazole

Trimethoprim was commonly used in combination with sulfamethoxazole, a sulfonamide antibiotic, which inhibits an earlier step in the folate synthesis pathway (see diagram above). This combination, also known as co-trimoxazole, TMP-sulfa, or TMP-SMX, results in an in vitro synergistic antibacterial effect by inhibiting successive steps in folate synthesis, this claimed benefit was not seen in general clinical use.[1] [2] Its use has been declining due to reports of sulfamethoxazole bone marrow toxicity, resistance and lack greater efficacy in treating common urine and chest infections,[3][4][5][6] and side effects of antibacterial sulfonamides. As a consequence, the use of co-trimoxazole was restricted in 1995.[7]

Clinical indications

Trimethoprim, used as monotherapy, is indicated for the prophylaxis and treatment of urinary tract infections (cystitis). Co-trimoxazole, with its greater efficacy against a limited number of bacteria, remains indicated for some infections; for example, it is used as prophylaxis in patients at risk for Pneumocystis jirovecii pneumonia (e.g. AIDS patients and those with some hematological malignancies) and as therapy in Whipple's disease.

Footnotes

  1. Brumfitt W, Hamilton-Miller JM (1993). "Reassessment of the rationale for the combinations of sulphonamides with diaminopyrimidines". J Chemother. 5 (6): 465–9. PMID 8195839. Unknown parameter |month= ignored (help)
  2. Brumfitt W, Hamilton-Miller JM (1994). "Limitations of and indications for the use of co-trimoxazole". J Chemother. 6 (1): 3–11. PMID 8071675. Unknown parameter |month= ignored (help)
  3. Bean DC, Livermore DM, Papa I, Hall LM (2005). "Resistance among Escherichia coli to sulphonamides and other antimicrobials now little used in man". J Antimicrob Chemother. 56 (5): 962–4. PMID 16150859. Unknown parameter |month= ignored (help)
  4. Felmingham D, Reinert RR, Hirakata Y, Rodloff A (2002). "Increasing prevalence of antimicrobial resistance among isolates of Streptococcus pneumoniae from the PROTEKT surveillance study, and compatative in vitro activity of the ketolide, telithromycin". J Antimicrob Chemother. 50 (Suppl S1): 25–37. PMID 12239226. Unknown parameter |month= ignored (help)
  5. Johnson JR, Manges AR, O'Bryan TT, Riley LW (2002). "A disseminated multidrug-resistant clonal group of uropathogenic Escherichia coli in pyelonephritis". Lancet. 359 (9325): 2249–51. PMID 12103291. Unknown parameter |month= ignored (help)
  6. Lawrenson RA, Logie JW (2001). "Antibiotic failure in the treatment of urinary tract infections in young women". J Antimicrob Chemother. 48 (6): 895–901. PMID 11733475. Unknown parameter |month= ignored (help) - suggest some small advantage in UTIs
  7. "Co-trimoxazole use restricted". Drug Ther Bull. 33 (12): 92–3. 1995. PMID 8777892. Unknown parameter |month= ignored (help)

External links

Template:Sulfonamides and trimethoprim


de:Trimethoprim hu:Trimetoprim sk:Trimetoprim sv:Trimetoprim th:ไตรเมโทพริม


Template:WikiDoc Sources